Biochemical Engineering

GSK says RSV vaccine shows 94% efficacy in severe disease

GSK says RSV vaccine shows 94% efficacy in severe disease

13th October 2022

This morning, GSK revealed the results from its pivotal AReSVi-006 trial of the RSV shot – called RSVPreF3 OA – having said earlier this year that the study was positive. Now, more details of the data have been revealed with an overall protective efficacy against RSV lower respiratory tract disease of 82.6% in the study, which involved adults aged 60 years and above, meeting the study’s main objective. Source: PharmaPhorum 13/10/2022


Back to group news